কানাডা - ফরাসি - Health Canada

emd serono, a division of emd inc., canada - interféron bêta-1a; interféron bêta-1a - trousse - 8.8mcg; 22mcg - interféron bêta-1a 8.8mcg; interféron bêta-1a 22mcg - immunomodulatory agents

ব্রাজিল - পর্তুগীজ - ANVISA (Agência Nacional de Vigilância Sanitária)

fundaÇÃo oswaldo cruz - betainterferona 1a - imunomodulador

কানাডা - ফরাসি - Health Canada

biogen canada inc - peginterfÉron bÊta-1a - liquide - 63mcg - peginterfÉron bÊta-1a 63mcg - interferons

কানাডা - ফরাসি - Health Canada

biogen canada inc - peginterfÉron bÊta-1a - liquide - 94mcg - peginterfÉron bÊta-1a 94mcg - interferons

কানাডা - ফরাসি - Health Canada

biogen canada inc - peginterfÉron bÊta-1a - liquide - 125mcg - peginterfÉron bÊta-1a 125mcg - interferons

কানাডা - ফরাসি - Health Canada

biogen canada inc - peginterfÉron bÊta-1a; peginterfÉron bÊta-1a - trousse - 63mcg; 94mcg - peginterfÉron bÊta-1a 63mcg; peginterfÉron bÊta-1a 94mcg - interferons

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

merck sharp & dohme b.v. - peginterferon alfa-2b - hepatitis c, chronic - immunostimulants, - adults (tritherapy)pegintron in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-c (chc) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.please refer to the ribavirin and boceprevir summaries of product characteristics (smpcs) when pegintron is to be used in combination with these medicines.adults (bitherapy and monotherapy)pegintron is indicated for the treatment of adult patients (18 years of age and older) with chc who are positive for hepatitis-c-virus rna (hcv-rna), including patients with compensated cirrhosis and / or co-infected with clinically stable hiv.pegintron in combination with ribavirin (bitherapy) is indicated for the treatment of chc infection in adult patients who are previously untreated including patients with clinically stable hiv co-infection and in adult patients who have failed previous treatment with interferon-alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon-alpha monotherapy.interferon monotherapy, including pegintron, is indicated mainly in case of intolerance or contraindication to ribavirin.please refer to the ribavirin smpc when pegintron is to be used in combination with ribavirin.paediatric population (bitherapy)pegintron is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents who have chc, previously untreated, without liver decompensation, and who are positive for hcv-rna.when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. the decision to treat should be made on a case-by-case basis.please refer to the ribavirin smpc for capsules or oral solution when pegintron is to be used in combination with ribavirin.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

merck europe b.v.  - interferon beta-1a - scleroză multiplă - imunostimulante, - rebif este indicat pentru tratamentul:pacienți cu un eveniment demielinizant unic cu un proces inflamator activ, dacă diagnostice alternative au fost excluse, iar dacă sunt determinate pentru a fi la risc ridicat de a dezvolta din punct de vedere clinic definit scleroza multipla;pacienții cu scleroză multiplă recurent. În studiile clinice, aceasta a fost caracterizată prin două sau mai multe exacerbări în ultimii doi ani. eficacitatea nu a fost demonstrată la pacienții cu scleroză multiplă secundar progresivă în curs de desfășurare, fără recidivă activitate.

ইউরোপীয় ইউনিয়ন - ফরাসি - EMA (European Medicines Agency)

merck europe b.v.  - interféron bêta-1a - sclérose en plaque - les immunostimulants, - rebif est indiqué pour le traitement des patients avec un seul démyélinisante événement avec un processus inflammatoire actif, si d'autres diagnostics ont été exclues, et si elles sont considérées comme à haut risque de développer une sclérose en plaques cliniquement définie;les patients atteints de sclérose en plaques récurrente. dans les essais cliniques, cela a été caractérisée par deux ou plusieurs exacerbations aiguës dans les deux années précédentes. l'efficacité n'a pas été démontrée chez les patients atteints de sclérose en plaques secondairement progressive, sans suivi de rechute de l'activité.

ইউরোপীয় ইউনিয়ন - স্পেনীয় - EMA (European Medicines Agency)

bayer ag  - interferón beta-1b - esclerosis múltiple - inmunoestimulantes, - betaferon está indicado para el tratamiento ofpatients con un solo evento desmielinizante con un activo proceso inflamatorio, si es lo suficientemente grave como para justificar un tratamiento con corticosteroides por vía intravenosa, si diagnósticos alternativos han sido excluidos, y si están decididos a estar en alto riesgo de desarrollar esclerosis múltiple clínicamente definida;los pacientes con recaída-remisión de esclerosis múltiple y dos o más recaídas en los últimos dos años;los pacientes con esclerosis múltiple secundaria progresiva con la enfermedad activa, evidenciado por las recaídas.